NL-OMON30222
尚未招募
不适用
The effect of a 12-week multidisciplinary treatment on the vascular function in obese children in the age of 8-17 years. - Treatment of obesity in children (8-17 years)
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 15 人待定
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- obesity
- 发起方
- niversitair Medisch Centrum Sint Radboud
- 入组人数
- 15
- 状态
- 尚未招募
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Aged 8\-17 years
- •Obesity (based on the international guidelines for obesity in children, see figure 1 in appendix 1\)
- •Signed informed consent
排除标准
- •Metabolic, muscular or neurologic disease
- •Specific syndroms in which obesity is an inclusion criterium (Prader\-Willi syndrom)
结局指标
主要结局
未指定
相似试验
尚未招募
3 期
A study to evaluate efficacy and safety of combination of Glycopyrronium 25mcg/ Arformoterol 15mcg solution for inhalation in patients with chronic obstructive pulmonary disease.Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecifiedCTRI/2020/05/025323Glenmark Pharmaceuticals Ltd
进行中（未招募）
3 期
Efficacy and safety of low dose QMF149 (150/80 microgram)compared with MF Twisthaler® (200 microgram) in patients suffering from asthma.Health Condition 1: null- AsthmaCTRI/2017/07/009000ovartis Healthcare Private Limited
进行中（未招募）
1 期
Efficacy and safety of low dose QMF149 (150/80 microgram) compared with MF Twisthaler® in patients with asthmaEUCTR2016-000472-22-LTovartis Pharma Services AG802
进行中（未招募）
1 期
Efficacy and safety of low dose QMF149 (150/80 microgram) compared with MF Twisthaler® in patients with asthmaAsthmaMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2016-000472-22-SKovartis Pharma Services AG802
进行中（未招募）
1 期
Efficacy and safety of low dose QMF149 (150/80 microgram) compared with MF Twisthaler® in patients with asthmaEUCTR2016-000472-22-DEovartis Pharma Services AG802